ClinicalTrials.gg

Program

PF-08098488

A development code.

Its studies are mostly in Esophageal Neoplasms, led by Pfizer.

Furthest: phase 1, since Oct 12, 20261 company-led study, 1 open or runningNext primary completion: Jan 26, 2031 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer11 open or runningphase 1since Oct 12, 2026Oct 12, 2026Jan 26, 2031phase 1 · NCT07903415

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 12, 2026First study: phase 1 study in Esophageal NeoplasmsFirst studyNCT07903415 · 280 planned · United States

Ahead

  1. Jan 26, 2031Primary completion: phase 1 study in Esophageal NeoplasmsNCT07903415

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07903415Esophageal Neoplasms · United States1RecruitingJan 26, 2031280

How it is read

Names in the registry

  • “PF-08098488”, 1 entry

Codes read as this program: PF08098488.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.